Investigational drug · Phase 3
ABBV-722
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Rheumatoid Arthritis, Systemic Sclerosis.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
8
Any phase or sponsor naming "ABBV-722"
First trial start
2026
Dec 7, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ABBV-722", any sponsor or status.
Conditions studied
As listed on its trial records.
- Rheumatoid Arthritis
- Systemic Sclerosis
Approved drugs for the same conditions: Rheumatoid arthritis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "ABBV-722" as an intervention, largest first.
- A Study to Evaluate the Safety and Efficacy (How Well the Study Treatment Works) of ABBV-2294 in Adult Participants With Systemic Sclerosis That Are Currently Receiving Local Standard of Care Treatment, and to Determine the Best Dose of ABBV-2294 to be Evaluated Further.Pivotal-lookingNot yet recruiting
AbbVieAbbVie (ABBV)
NCT07933211 · 580 participants (planned) · Start Dec 11, 2026 · Primary completion Jun 2035
Drug: ABBV-722; Upadacitinib and 2 more · For: Systemic Sclerosis
- Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid ArthritisPivotal-lookingNot yet recruiting
AbbVieAbbVie (ABBV)
NCT07904754 · 250 participants (planned) · Start Dec 7, 2026 · Primary completion Jul 2029
Drug: ABBV-722; Upadacitinib · For: Rheumatoid Arthritis
AbbVieAbbVie (ABBV)
NCT06673238 · 95 participants · Start Oct 29, 2024 · Primary completion Jun 25, 2026
Drug: ABBV-722; Placebo · For: Healthy Volunteer
Sites: Cypress, California; Grayslake, Illinois
AbbVieAbbVie (ABBV)
NCT07425899 · 16 participants · Start Feb 26, 2026 · Primary completion Jun 5, 2026
Drug: ABBV-722; Upadacitinib · For: Healthy Volunteer
Sites: Grayslake, Illinois
AbbVieAbbVie (ABBV)
NCT07502417 · 15 participants · Start Mar 27, 2026 · Primary completion Jul 2, 2026
Drug: Ethinyl Estradiol + Levonorgestrel; ABBV-722 · For: Healthy Volunteer
Sites: Grayslake, Illinois
- A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adult ParticipantsCompleted
AbbVieAbbVie (ABBV)
NCT07599761 · 12 participants · Start May 7, 2026 · Primary completion Sep 3, 2026
Drug: ABBV-722; Itraconazole · For: Healthy Volunteers
Sites: Grayslake, Illinois
AbbVieAbbVie (ABBV)
NCT07567781 · 12 participants · Start Apr 30, 2026 · Primary completion Jul 21, 2026
Drug: ABBV-722; Midazolam and 4 more · For: Healthy Volunteers
Sites: Grayslake, Illinois
AbbVieAbbVie (ABBV)
NCT07361367 · 11 participants · Start Jan 15, 2026 · Primary completion Mar 23, 2026
Drug: ABBV-722 · For: Healthy Volunteers
Sites: Grayslake, Illinois
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Rheumatoid Arthritis
- IanalumabVAY736, VAY736 AIPhase 318 trials
Novartis · Primary Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus, Sjogren Syndrome
- AfimkibartRO7790121, RVT-3101Phase 312 trials
Roche (Genentech) · Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohns Disease, Atopic Dermatitis
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- TLL-018Phase 38 trials
Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria
- IMVT-1402Phase 37 trials
Immunovant Sciences GmbH · Graves' Disease, Rheumatoid Arthritis, Subacute Cutaneous Lupus Erythematosus
- FilgotinibGS-6034, GLPG0634Phase 36 trials
Alfasigma S.p.A. · Ulcerative Colitis, Polyarticular Course Juvenile Idiopathic Arthritis, Juvenile Idiopathic Arthritis (JIA)
- LNK01001Phase 33 trials
Lynk Pharmaceuticals Co., Ltd · Ankylosing Spondylitis, Atopic Dermatitis, Rheumatoid Arthritis
- LevilimabPhase 31 trial
Biocad · Rheumatoid Arthritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AbbVie.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.